Stryker is in discussions to acquire Boston Scientific's neuromodulation business for about $1.5 billion, and an agreement over the unit may be disclosed next week, according to three people familiar with the potential deal. An analyst with Cannacord Genuity said the purchase would supplement Stryker's line of pain-management devices for back problems.

Full Story:

Related Summaries